Cargando…

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer

Castration-resistant prostate cancer is an incurable disease. To date, six agents-abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T- have shown clinical efficacy in phase III clinical trials, leading to their FDA approval. Patients are typically sequenced through most or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Thu-Cuc, Bajwa, Ravneet, Bari, Shahla, Ali, Azka, Paul Skelton, William, Federico, Roland-Austin, Bishnoi, Rohit, Wray, Justin W, Zlotecki, Robert A, Dang, Long H, Muzaffar, Jameel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761507/ https://www.ncbi.nlm.nih.gov/pubmed/29340160 http://dx.doi.org/10.1093/omcr/omx078

Ejemplares similares

Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy
por: Wray, Justin, et al.
Publicado: (2017)

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
por: Schoenhals, Jonathan E., et al.
Publicado: (2021)

Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience
por: Skelton, William P, et al.
Publicado: (2019)

Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease
por: Reshko, Leonid B., et al.
Publicado: (2021)

Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases
por: Berber, Tanju, et al.
Publicado: (2022)

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression
por: Ho, Chin-Beng, et al.
Publicado: (2023)

A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer
por: Pan, Kelsey, et al.
Publicado: (2021)

Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?
por: Bari, Shahla, et al.
Publicado: (2022)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer
por: Weykamp, Fabian, et al.
Publicado: (2020)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy to a Splenic Metastasis in Oligoprogressive Non-small Cell Lung Cancer
por: Kim, Daniel W., et al.
Publicado: (2019)

The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review
por: Yan, Bernie, et al.
Publicado: (2023)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
por: Guida, Michele, et al.
Publicado: (2019)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

A case of repeat oligoprogressive castration‐resistant prostate cancer treated with pulmonary metastasectomy
por: Soma, Takahiko, et al.
Publicado: (2023)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Stereotactic Body Radiation Therapy for the Treatment of Locally Recurrent and Oligoprogressive Non-Small Cell Lung Cancer: A Single Institution Experience
por: Katz, Leah M., et al.
Publicado: (2022)

Stereotactic Radiation for Oligometastatic and Oligoprogressive Stage IV Breast Cancer: A Case-based Review
por: Freedman, Gary M., et al.
Publicado: (2023)

Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer Recurrence Revealed by Choline PET/CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
por: Bishnoi, Rohit, et al.
Publicado: (2017)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors
por: Ji, Xiaoqin, et al.
Publicado: (2021)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
por: Rossi, Antonio, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study
por: Bishnoi, Rohit, et al.
Publicado: (2019)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
por: Shah, Chintan, et al.
Publicado: (2020)

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
por: Wang, Zhen, et al.
Publicado: (2021)

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
por: Sindhu, Kunal K., et al.
Publicado: (2022)

Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies
por: Le, Uyen-Thao, et al.
Publicado: (2023)

Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma
por: Muzaffar, Jameel, et al.
Publicado: (2021)

How do we define “castration” in men on androgen deprivation therapy?
por: Itty, Sarin, et al.
Publicado: (2020)

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’
por: Bravo, Isabel
Publicado: (2018)

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer
por: Li, Shuai, et al.
Publicado: (2019)

Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer
Publicado: (2022)

Low Grade Lymphoma Mimicking Metastatic Urothelial Carcinoma: When Do We Need Further Histologic Staging?
por: Ali, Azka, et al.
Publicado: (2016)

Increased abscopal responses after radiation therapy for oligoprogressive patients receiving immune checkpoint inhibitors?
por: Doyen, Jérôme, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2sldepmnaovn6ne1pmc64k1u03